Last reviewed · How we verify
Tavo
At a glance
| Generic name | Tavo |
|---|---|
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients (PHASE2)
- CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2) (PHASE1)
- Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC (PHASE2)
- Trial of pIL-12 Electroporation Malignant Melanoma (PHASE2)
- IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer (PHASE2)
- Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma (PHASE2)
- Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC) (PHASE2)
- Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tavo CI brief — competitive landscape report
- Tavo updates RSS · CI watch RSS
- H. Lee Moffitt Cancer Center and Research Institute portfolio CI